Elevation Oncology Inc ELEV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:49 PM EDT
5.05quote price arrow down-0.08 (-1.56%)
Volume
1,151
Close
5.13quote price arrow up+0.12 (+2.40%)
Volume
436,685
52 week range
0.36 - 5.89
Loading...
  • Open5.04
  • Day High5.26
  • Day Low4.92
  • Prev Close5.01
  • 52 Week High5.89
  • 52 Week High Date05/26/23
  • 52 Week Low0.36
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap249.58M
  • Shares Out48.65M
  • 10 Day Average Volume0.68M
  • Dividend-
  • Dividend Yield-
  • Beta1.36
  • YTD % Change855.31

KEY STATS

  • Open5.04
  • Day High5.26
  • Day Low4.92
  • Prev Close5.01
  • 52 Week High5.89
  • 52 Week High Date05/26/23
  • 52 Week Low0.36
  • 52 Week Low Date11/13/23
  • Market Cap249.58M
  • Shares Out48.65M
  • 10 Day Average Volume0.68M
  • Dividend-
  • Dividend Yield-
  • Beta1.36
  • YTD % Change855.31

RATIOS/PROFITABILITY

  • EPS (TTM)-1.53
  • P/E (TTM)-3.36
  • Fwd P/E (NTM)-5.94
  • EBITDA (TTM)-40.299M
  • ROE (TTM)-88.03%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)54.99%

EVENTS

  • Earnings Date05/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Elevation Oncology Inc

 

Profile

MORE
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1...
Steven Elms
Chairman of the Board
Joseph Ferra Jr.
President, Chief Executive Officer, Director
Tammy Furlong CPA
Chief Financial Officer
Address
101 Federal Street, Suite 1900
Boston, MA
02110
United States

Top Peers

SYMBOLLASTCHG%CHG
INMB
INmune Bio Inc
11.75+0.12+1.03%
DSGN
Design Therapeutics Inc
4.03+0.12+3.07%
OVID
Ovid Therapeutics Inc
3.05UNCHUNCH
ATOS
Atossa Therapeutics Inc
1.80-0.03-1.64%
DRTS
Alpha Tau Medical Ltd
2.95UNCHUNCH